Document Detail


Long-term myocardial preservation: thromboxane production and coronary resistance.
MedLine Citation:
PMID:  6688844     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In a series of 18 experiments on long-term myocardial preservation we evaluated whether vasoactive substances like thromboxane and prostacyclin are associated with the secondary increase in coronary resistance during preservation perfusion of the canine heart. In a control group (n = 12) and in a group treated with a specific thromboxane synthetase inhibitor (OKY 1581) coronary resistance was measured at 10 and 30 min, and at 1, 4, and 24 hr. At the same time intervals thromboxane A2 and prostacyclin (PGI2) production were determined as TXB2 and 6-keto PGF1 alpha, respectively. After OKY 1581 treatment no increase in TXB2 occurred and no secondary increase in coronary resistance was observed, while in the control group both TXB2 levels and resistance increased (P less than 0.01); 6-keto PGF1 alpha levels showed the same increase in control and in treated hearts. From this study it is concluded that during 24-hr myocardial preservation the characteristic secondary increase in coronary resistance is related to thromboxane production in the heart and is prevented by inhibition of thromboxane synthetase.
Authors:
G L van Rijk; M Foegh; P W Ramwell; M Goldman; R R Lower
Related Documents :
1371034 - Preservation of endothelium-dependent vasodilation in the spastic segment of the human ...
2044564 - Torsades de pointes after intracoronary papaverine.
8234834 - Constriction of canine coronary arteries by platelet activating factor after brief isch...
162474 - Augmented venous return: protection of the ischemic myocardium during endotoxemia.
2116434 - The renin-angiotensin system in hypertension: an update.
16330114 - Risk factors of ventricular tachyarrhythmias after coronary artery bypass grafting.
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The Journal of surgical research     Volume:  35     ISSN:  0022-4804     ISO Abbreviation:  J. Surg. Res.     Publication Date:  1983 Nov 
Date Detail:
Created Date:  1983-12-17     Completed Date:  1983-12-17     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0376340     Medline TA:  J Surg Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  417-20     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
6-Ketoprostaglandin F1 alpha / analysis
Animals
Coronary Circulation* / drug effects
Dogs
Heart*
Methacrylates / pharmacology
Myocardium / metabolism
Organ Preservation*
Perfusion
Thromboxane B2 / analysis
Thromboxane-A Synthase / antagonists & inhibitors
Thromboxanes / biosynthesis*
Time Factors
Vascular Resistance / drug effects
Grant Support
ID/Acronym/Agency:
AM 30499/AM/NIADDK NIH HHS; HL 17516/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Methacrylates; 0/Thromboxanes; 54397-85-2/Thromboxane B2; 58962-34-8/6-Ketoprostaglandin F1 alpha; 75987-08-5/2-methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic acid; EC 5.3.99.5/Thromboxane-A Synthase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Speech signal presentation to the totally deaf.
Next Document:  Hodgkin disease clinical stages I, II, and III (A, B): results of radiotherapy with or without chemo...